Pharming N : BlackRock Inc. - Pharming Group N.V. - Leiden
November 02, 2022 at 04:27 pm EDT
Share
Back
BlackRock Inc. - Pharming Group N.V. - Leiden
Below you will find information from the register substantial holdings and gross short positions. The information has been provided by the organisation.
Date of transaction01 nov 2022
Person obliged to notifyBlackRock Inc.
Issuing institutionPharming Group N.V.
Registration Chamber of Commerce28048592
Place of residenceLeiden
Previous result
Next result
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Gewoon aandeel
Number of shares3.942.513,00
Number of voting rights3.942.513,00
Capital interestPotentieel
Voting rightsPotentieel
Manner of disposalMiddellijk
(BlackRock, Inc.)
SettlementFysieke levering
Gewoon aandeel
Number of shares15.446.658,00
Number of voting rights15.709.259,00
Capital interestReëel
Voting rightsReëel
Manner of disposalMiddellijk
(BlackRock, Inc.)
Contract for difference
Number of shares16.998,00
Number of voting rights16.998,00
Capital interestPotentieel
Voting rightsPotentieel
Manner of disposalMiddellijk
(BlackRock, Inc.)
SettlementIn contanten
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Kapitaalbelang
Total holding2,96 %
Directly real0,00 %
Directly potential0,00 %
Indirectly real2,36 %
Indirectly potential0,60 %
Stemrecht
Total holding3,00 %
Directly real0,00 %
Directly potential0,00 %
Indirectly real2,40 %
Indirectly potential0,60 %
Date last update: 02 November 2022
Share information
Share on:Share this
Attachments
Original Link
Original Document
Permalink
Disclaimer
Pharming Group NV published this content on 01 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 November 2022 20:26:09 UTC.
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.